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Human immunodeﬁciency virus type 1 (HIV-1) reverse transcrip-
tase (RT) is a major target to curtail replication of the virus. Therefore,
nucleoside and nucleotide RT inhibitors (NRTI) are important compo-
nents of highly active antiretroviral therapy (HAART) and contribute
signiﬁcantly in reducing viral load, often below the detection limit (b50
copies). Biochemical studies have shown that several dideoxynucleo-
side (ddN) compounds including 2′,3′-dideoxy-3′thiacytidine (3TC),
2′,3′-dideoxycytidine (ddC), and 2′,3′-dideoxyinosine (ddI) are potent
inhibitors of viral RT-catalyzed cDNA synthesis (Furman et al., 1986;
Goody et al., 1991). Incidentally, HIV-1 develops resistance to the target
ddN reversing the beneﬁt of the antiretroviral. While 3TC selects for a
highly resistant mutation M184V in the catalytic region of RT, several
ddN-related mutations appear in the ﬂexible β3–β4 loop formed in the
ﬁngers sub-domain of the 66 kDa subunit of HIV-1 RT (Huang et al.,
1998).
One of the key RT mutations which is selected in β3–β4 loop by
several nucleoside analogues, a potent nucleotide analogue, tenofovir
disoproxil fumarate (TDF) and abacavir (ABC) is K65R (Zhang et al.,
1994; Gu et al., 1994; Sharma et al., 2004a (review); Bennett et al.,
2009). One of the important features of K65R is that it predominantlyappears with non-thymidine analoguemutations (TAMs) (Parikh et al.,
2006, 2007). Clinical trials have revealed that the less common
mutations that occur during virologic failurewith non thymidine analog
regimens include K65N, K70E/G, and Y115F (Delaugerre et al., 2005;
Moyle et al., 2005; Ross et al., 2006; Bartlett et al., 2006; Bradshaw et al.,
2007; Shafer and Schapiro, 2008). Drug susceptibility analysis revealed
that K65N and K70E/G have a resistance proﬁle similar to K65R, but
apparently cause decreased resistance than K65R to ABC, ddI, TDF, 3TC
and emitricitabine (FTC) (see references in the review by Shafer and
Schapiro, 2008). However, in the era of combination therapy, combina-
tions of mutations are likely to be selected both in vivo and in vitro,
altering resistance of the viruses. For example drug susceptibility assays
on the viruses developed during in vitro passaging of HIV-1 in the
presence of FTC+TFV showed the selection of K65N+K70R viruses
that had a 3.6- and 39-fold increase in the resistance for TFV and FTC
respectively in comparison to wild type HXB2D virus (Margot et al.,
2006). According to our recent search of HIV Drug Resistance Database
of Stanford University, the presence of K65N mutation has been
documented in twenty two isolates from 21 subjects by 14 different
groups (Rhee et al., 2003 and http://hivdb.stanford.edu/cgi-bin/RTMut.
cgi; searched on December 2, 2010). The data regarding direct
comparison of the properties of the viruses containing K65R and K65N
mutations are lacking in the literature.
HIV RT is highly ﬂexible and allows novel mutation(s) to be selected
in order to replicate under speciﬁc selection pressure. As newer
nucleoside analogues are being employed to suppress the HIV
replication during viral breakthrough, the selection of less frequent
mutation(s) is likely to occur due to the variable selection pressure
posed by the combination of antiretroviral agents. Thus, it is important
35H. Chunduri et al. / Virology 414 (2011) 34–41not only to monitor genomic proﬁles of clinical isolates but also to
understand the effect of mutation on replication capacity and enzyme
kinetics.
Based upon the aforementioned fact regarding the lowprevalence of
viruses containing K65N mutation, we hypothesized that HIV-1
containing K65N RT mutation will have attenuated replication in
comparison to the viruses containing K65R mutation. We performed a
series of PBM Cell-based replication assays and in vitro RT processivity
assays. Our results show that K65Nviruses have a signiﬁcant decrease in
the replication capacity (RC) in comparison to K65R viruses. This
attenuated replication appears to be due to a severe defect in the ability
of K65N RT to incorporate natural dNTP into homopolymer poly A RNA
during reverse transcription.
Results
Inefﬁcient replication of viruses containing K65N mutation in comparison
to viruses with K65R mutation in PBM cells
To compare the effect of K65N and K65R mutations on viral
replication, we infected PBM cells with WT, K65R and K65N viruses at
different MOIs (0.001, 0.01, 0.1) and measured RT activity in a 14 day
assay (Fig. 1A, B, C). As the measurement of RT activity may impact on
actual differences in RC values due to altered RTs of mutant viruses, weFig. 1. Demonstration of inefﬁcient replication of viruses containingK65Nmutation in PBMcells
supernatantswere collected at various timepoints tomeasure replication efﬁciencies ofmutant
both RT activity and HIV antigen p24 was determined for infections done at 0.01 (B) to monito
comparison to K65R viruses. More pronounced differences were observed in the production of R
production ofRT activity. Comparing doublemutant viruses, K65N+L74Vvirus showedabsence
2004b) a longer (until day 10) lag period than for K65R+L74V viruses.also determined HIV antigen p24 production at MOI 0.01 (Fig. 1D). The
growth pattern of viruses in Fig. 1 clearly shows the increased
replication efﬁciency of K65R viruses in comparison to K65N viruses.
Since optimal antigen p24 production for K65N viruses was obtained at
day 10 post infection (Fig. 1D), we calculated RCs of K65R and K65N
viruses ondays 12 and 14 in three independent assays. The RCs for K65R
were: 0.48, 0.50 and 0.45 and 0.45, 0.49 and 0.43 on days 12 and 14,
respectively. In contrast, K65N viruses had decreased RCs of 0.25, 0.33
and 0.23 and 0.22, 0.30 and 0.21 on days 12 and 14, respectively. The
paired analysis by Student t-test showed a signiﬁcant decrease in RCs of
K65N viruses on day 12 (p=0.002) and day 14 (p=0.0018) in
comparison to viruses containing K65R mutations.
Decrease in replication efﬁciency of the viruses containing K65N mutation
in comparison to viruses with a K65R mutation in MT-2 cells
Previous studies have shown that the T-cell lines have an increased
deoxynucleotide triphosphate (dNTP) pools in comparison to primary
cells (PBM) (Larder et al., 1995; Back et al., 1996),wewished to evaluate
the growth kinetics of K65N and K65R viruses in MT-2 cells. Infections
were carried out at a lower MOI (0.001) to avoid a rapid depletion of
MT-2 cells during the duration of assay. In comparison to PBM cells
where the measurable RT activity was delayed until day 12 of infection
(Fig. 1A), we were able to measure RT activity after day 7 in MT-2 cells.. PHA-stimulated PBMcells (10×106)were infectedwith 293T-derivedviruses and culture
viruses. RT activitywasdetermined for infectionsdoneatMOIs of 0.001 (A), and 0.1 (C) and
r viral replication. Plot shows 2-fold decreased antigen p24 production for K65N viruses in
T activity between K65R and K65N viruses as the latter virus had 3–6-fold decrease in the
of antigenp24 andRTactivity until day 14 of assay and as shownpreviously (Sharmaet al.,
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activity on days 12 and 14 in comparison to K65N viruses, suggesting
inefﬁcient replication of K65N viruses in MT-2 cells (Fig. 2).Absence of productive viral infection in viruses containing various point
mutations at RT codon 65 in the background of L74V mutation
Previous studies have shown that amino acid changes other than
arginine at RT codon 65 results in the absence of any RT activity,
suggesting the signiﬁcance of IKKK (RT codons 63–66) motif in β3–β4
linkage groupof RT (Huang et al., 1998).Wehavepreviously shown that
mutations K65R and L74V are incompatible and a R→K reversion
occurs during initiation of replication of K65R+L74V viruses in PBM
cells in the absence of selection pressure (Sharma et al., 2004b). In
contrast to L74V, thepresence of L74I in thebackgroundof K65R leads to
the generation of a virus which is replication competent due to an
increased processivity of K65R+L74I RT (Chunduri et al., 2011). We
wished to assess the effect of an interaction of L74V with side chains of
different amino acids at codon 65. In order to assess the effect of amino
acid polymorphism at RT codon 65 in the background of L74V, we
created various point mutants. The different groups of amino acids
selected were: positively charged hydrophilic, Arginine (R); negatively
charged hydrophilic glutamic acid (E); non-polar hydrophobic alanine
(A) and isoleucine (Ile); polar hydrophilic theronine (T), asparagine (N)
and glutamine (Q). Single pointmutants (K65R, K65E, K65A, K65I, K65T,
K65N, K65Q) and doublemutants (K65R+L74V, K65E+L74V, K65A+
L74V, K65I+L74V, K65T+L74V, K65N+L74V, K65Q+L74V) were
created in NL4-3 background. Viruses were produced in 293T cells and
infectionswere normalized on thebasis of equivalent amountof antigen
p24. Replication kinetics assays showed the absence of any measurable
RT activity in PBM cells transfected with various point mutants and
doublymutant viruses except K65R andK65Nviruses (data not shown).
A low level of replication was observed in MT-2 cells but the MT-2 cell-
derivedviruses failed to initiate any replication in PBMcells. Theamount
of RT activity produced by different mutants was in a range of 1.3×103
to 4.5×104. The RT activity produced byWT, K65R and K65N viruses on
day 7 was 3.3×106, 1.5×106 and 7.0×104 (2.0×105 on day 14)
respectively (Table 2). Our results conﬁrm previous observations that
amino acid changes other than K65R and K65N (this study) are not
tolerated by RT. Also, similar to K65R+L74V other amino acid changes
at RT codon 65 in the background of L74V resulted in an altered RT
which failed to replicate in PBM cells.Fig. 2. Inefﬁcient replication of K65N viruses in MT-2 cells. Three million MT-2 cells
(0.5×106/ml) were infected with 0.001 MOI of 293T cell-derived viruses. Culture
supernatants were collected at various time points and RT activity was determined. The
graph shows a 2-fold decreased production of RT activity on days 12 and 14 by K65N
viruses in comparison to K65R viruses.Viruses containingmutations K65RandK65Nhave similar resistance to TFV
and ddI
Since amino acid changes other than arginine and asparagine at
codon 65 of HIV-1 RT did not support virus production and a second site
mutation L74V did not compensate for the replication attenuation (as
shown above), we compared drug susceptibilities of viruses containing
K65RandK65Nmutations. Bothof theviruses showedsimilar resistance
to TFV and ddI in comparison to WT NL4-3 virus (Table 3). Viruses
containing K65Rmutation showed 6-fold and 5-fold change in the drug
susceptibilities to TFV and ddI respectively, conﬁrming previous
observations by other laboratories (Margot et al., 2006; Brenner et al.,
2006).Wewere unable toﬁndany previous report comparingK65Rand
K65N drug susceptibilities under identical assay conditions.
Demonstration of a signiﬁcant decrease in the processivity of RT containing
K65N mutation in comparison to RT with K65R mutation
Previous studieshave shown theviral attenuated-relateddecrease in
the RT processivity using template/primer homopolymer poly A-oligo
(dT) combination (Back et al., 1996; Back and Berkhout, 1997; Sharma
and Crumpacker, 1999; Sharma et al., 2009). We performed ﬁve
independent in vitro processivity assays to compare RTs containing
K65R and K65N mutations. The processivity assay was standardized to
assess the increase in the density of cDNA (α-32P TTP) bands with an
increase in the amount of RTwithout a change in the length of the cDNA
products in each lane. We calculated the percentage decrease in RT
activity of mutant viruses with respect to WT RT activity in a single
processive cycle. We found signiﬁcant reduction in K65N RT activity
(50–56%) in comparison to K65R RT activity (72–75%) (Fig. 3A).We
compared the highest cDNAbandgenerated byWT andmutant RTs.We
also compared the cDNA density of fragments in each lane. The highest
cDNA fragments generated by WT, K65R and K65N were 72, 65 and 48
nucleotides, respectively. The representative view of autoradiograph is
shown in Fig. 3B. The quantiﬁcation of the density of smaller cDNA
fragments (1–6 and 7–12) show non-signiﬁcant differences between
WT/K65N (p=0.115 and p=0.135) and K65R/K65N (p=0.38 and
p=0.21). However, comparing different groups of larger cDNA
fragments (13–18 to 43–48) between WT and K65N RT showed a
signiﬁcant decrease in cDNA densities of latter RT (13–18, p=0.04; 19–
24, p=0.005; 43–48, p=0.0001). Similarly, comparing cDNAdensity of
larger fragments (25–30 to 43–48) between K65R and K65N RTs
showeda signiﬁcantdecrease in the cDNAdensity (thereof processivity)
of fragments generated by K65N RT (25–30, p=0.006; 31–36,
p=0.002; 37–42, p=0.001; 43–48, p=0.0007) (Fig. 3C). Taken
together our data suggest that the processivity of RT containing K65N
is severely compromised in comparison to WT and K65R RT. These
observationsprovide strongevidence for amechanismof the attenuated
replication of viruses containing K65N mutation in comparison to the
viruses with K65R mutation.
Discussion
In this study, we have demonstrated that K→N amino acid change
at RT codon 65 leads to a highly attenuated virus in comparison to
K→R change. Furthermore, this attenuation is related to a signiﬁcant
decrease in in vitro RT processivity by K65N RT in relation to K65R RT.
These observations suggest that the mechanism for a low prevalence
of K65N mutation during clinical trials is due to a decrease in RCs.
Alternatively, the relatively high frequency of K65R in comparison to
K65N may be due to the fact that K65N viruses are attenuated. The
prevalence of K65R remained about 3.3–3.8% despite the use of TFV as
a component of combination regimen during clinical trials (Miller,
2004; Parikh et al., 2006 and 2007; McColl et al., 2008). In contrast the
selection of K65N is rare during clinical trials but the selection of this
mutation occurs both in vitro as well as in vivo under different
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report the emergence of K65N mutation was linked to a dramatic
decline in HIV replication capacity from baseline (RC=141%) to
12 weeks of therapy (RC=8.9%) (Ross et al., 2006). Since there were
additional NNRTI-selected mutations L100I and K103N present with
K65N in the clinical isolate, it was not possible to analyze the role of
K65N alone in the decreased RC observed. The development of K65N
mutation in that study was also associated with the decreased
susceptibilities to TFV (2-fold) and ddI (1.6-fold) approximately
(Ross et al., 2006). Our results suggest that due to a replication
disadvantage of K65N viruses in comparison to K65R viruses, the
selection of former will be more favorable in patients even with the
similar resistance proﬁle to TFV and ddI.
Interestingly, the selection of K65N is not treatment-speciﬁc and
occurs with various combinations of the antiviral treatments, such as
zidovudine (AZT)+ddI (Venturi et al., 1999), ABC+3TC+TDF
(Hoogewerf et al., 2003), efavirenz (EFV)+ddI+FTC (Saag et al., 2004),
EFV+ABC+3TC (Ross et al., 2006), AZT+3TC (Seyler et al., 2007), TDF+
3TC+NVP (nevirapine) (Hawkins et al., 2009), and stavudine (D4T)+
3TC+NVP (Hosseinipour et al., 2009; Iqbal et al., 2009; Manosuthi et al.,
2010). K65N has also been detected in chronically-infected drug naïve
patients (Brumme et al., 2007; Wang et al., 2007). Although infrequent,
the presence of K65N in drug naïve individuals and non-speciﬁc selection
during various treatments requires further attention.
Cell culture studies to select for drug resistance have shown that the
passaging of HIV-1 strain IIIb or HIV-1 LAI in the increasing concentra-
tions of FTCwith a ﬁxed concentration of TFV results in the replacement
of mutations K65R/K+M184I/M→K65R→K65N+K70R. When start-
ing virus containing A62V, K65R andM184I mutation was grown in the
presence of 32-fold the EC50 of FTC, the resultant pattern was A62V,
K65N, andK70R.However, increased FTCEC50 concentrations to 64- and
128-fold resulted in the selection of a virus containing A62V, K65R, and
M184V. It was speculated that the development of K65N+K70R
mutation at an intermediate FTC concentration represent a temporary
step in the development of resistance to FTC-TFV combination which
subsequently result in the selection of K65R+M184V (FTC N210-fold)
compared to K65N+K70R (FTC N39-fold) (Margot et al., 2006). This
decreased resistance is likely to be the result of K65N-induced
attenuated replication of the viruses as demonstrated in our analysis.
As TDF containing regimens continue to show promise in prevention of
HIV-1 transmission, we need to understand all the biologic conse-
quences of TDF resistance (Grant et al., 2010).
We further investigated the impact of different amino acid changes
at RT codon 65 with or without L74V on viral replication. We
demonstrate here that except K→R and K→N (this study), other
changes (K65A, K65E, K65Q, K65I and K65T) at RT codon 65 are not
tolerated by RT and result in non-viable viruses with a non-productive
infection in PBM cells. Also, this deleterious effect is not compensated in
the presence of L74V mutation. Interestingly, this is in contrast to our
previous observations on K65R+L74V viruses, which take longer toFig. 3. Demonstration of decreased processivity of RTs containing K65N mutation. Two
and four micro liters of WT, K65R and K65N virion-associated RTs were incubated with
template/primer poly (rA)-oligo (dT) in the presence of 50molar excess of trap poly (rC)-
oligo (dG) and α-32p TTP in a 50 μl reaction for 3 h. The RT activity during a single
processive cycle was determined by spotting 10 μl of reaction mixture on DE81 ﬁlter. The
average of 4 independent RT processivity assays is shown here (A). cDNAwere puriﬁed by
phenol/chloroform extraction from remaining 40 μl of reaction mixture. The puriﬁed
products were run on a 6% polyacrylamide gel electrophoresis. Wet gels were exposed to
autoradiography. cDNA fragments of different lengths and intensities are shown here (B).
The lengths (nt) of the largest fragment synthesizedbydifferent RTswere 72, 65and48 for
WT, K65R and K65N, respectively. Quantiﬁcation of cDNA bands synthesized byWT, K65R
andK65NRTswasdonebycapturing ahighdigitalized imageof autoradiograph.Groupsof
6 bands from bottom to top of each lane were scanned and quantiﬁed by Intelligent
Quantiﬁer software (Bio Image Systems, Inc., Jackson, MI). RT containing K65N mutation
showed a signiﬁcant decrease in the density of larger cDNA bands (25–48) in comparison
to K65R RT (C).develop post-infection and initiation of viral replication coincides with
the R→K reversion (Sharma et al., 2004b).
Previous studies have shown that other than K→R (K65R)
substitution at Lys65, such as K65E, K65Q, and K65A results in an RT
that exhibits signiﬁcantdecrease in thebinding afﬁnity (Km) for all dNTP
substrates, RT catalytic efﬁciency and the ability of mutant enzyme to
Table 1
Primers for site-directed mutagenesis at RT codon 65.
Intended change Primer sequence (5′→3′) Position in pNL4-3a
Isoleucine (I) CTGTCTTTTATCTTTATGGCA 2752-2732
Therionine (T) CTGTCTTTTGTCTTTATGGCA 2752-2732
Asparagine (N) CTGTCTTTGTTCTTTATGGCA 2752-2732
Alanine (A) CTGTCTTTTGCCTTTATGGCA 2752-2732
Glutamic acid (E) CTGTCTTTTTCCTTTATGGCA 2752-2732
Glutamine (Q) CTGTCTTTTTGCTTTATGGCA 2752-2732
Italic and bold letters indicate the intended change in nucleotides.
a Sequences were derived from proviral clone pNL4-3 (Adachi et al., 1986).
Fig. 3 (continued).
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previously that deletion of the β3–β4 loop, or a K65A substitution leads
to increased ﬁdelity of RT through due to an increase in dNTP selection
stringency (Sluis-Cremer et al., 2000; Garforth et al., 2010). Recent
studies using pre-steady-state kinetics have demonstrated that
substitutions Arg and ala at Lys65 results in a decreased efﬁciency of
mismatch extension, mainly through a decreased afﬁnity for the
incoming dNTP (Garforth et al., 2010). Taken together, these biochem-
ical studies provide evidence that the Lys65 is critical for functional
HIV-1 RT. We speculate that the low prevalence of K65R during clinical
trial is due to the fact that Lys65 is indispensable for the function of the
RT.
Clinical trials with a combination of FTC+ddI+EFV (n=286)
resulted in the development of K65N in one patient out of 13 who
experienced virological failure. Eleven out of 13 showed the presence of
NNRTI-associatedmutation. Fiveof these11patients developedM184V/
I in addition toNNRTImutation and1developed aK65Nmutation.None
of these subjects developed the L74V mutation. However, 3 out of 31
patients who experienced virological failure among D4T+ddI+EFV
group (n=285) showed the development of L74Vmutation (Saag et al.,
2004). Interestingly, in this study the FTC regimen (FTC, ddI, EFV)
appeared to demonstrate greater efﬁcacy compared with the stavudine
regimen (shown above). Our observations that the viruses containing
K65Nmutation in the background of L74V are highly attenuated and do
not support productive virus production in PBM cells are in agreement
with the lack of selection of L74V in the presence of K65N in the above
stated clinical observations.
Previous studies using puriﬁed RT and virion-associated RTs
containing K65R mutation have demonstrated the decreased proces-
sivity of K65R RT in comparison to WT RT with both heteropolymer as
well as homopolymer templates (White et al., 2002, Deval et al., 2004,
Sharma et al., 2009, Xu et al., 2009). Moreover K65R RTs of both clade B
and clade C viruses showed similar ﬁnding of diminished initiation
efﬁciency of mutant RTs at low dNTP concentrations (Xu et al., 2009).
These observations are in agreement with our observations that RT
containingK65Rmutation confers a decreased processivity in in vitroRT
assays using homopolymer poly A/oligo (dT) template/primer (Sharma
et al., 2009, and present study). Furthermore, our observations on the
signiﬁcant decrease in the processivity of K65N RT in comparison to
K65R RT suggest that the K→N change further alters the initiation
ability of K65N RT to incorporate natural dNTPs.
Lys65 is one of the ﬁve residues (Ile63, lys64, Lys65, trp71 and Arg72)
that form the part of β3–β4 loop in the ﬁngers domain of the 66kDa
subunit of HIV-1 RT (Huang et al., 1998). Comparing different RTs have
revealed that these ﬁve residues are conserved in all retroviral RTs
(Boyer et al., 1992). HIV-1 RT crystallographic analyses have shown thatin the RT/template-Primer-dNTP ternary complex, the guanidiumgroup
ofArg72 and the ε-aminogroupof Lys65 formsalt bridgeswith theα and
γ-phosphates of the bound dNTP substrate, respectively. These
signiﬁcant interactions assist both in the positioning of dNTP for base-
pairingwith the complementary template base aswell as for catalysis of
phosphodiester bond formation with the 3′-OH group of the terminal
nucleotide of the primer (Huang et al., 1998). The comparison of side
chains of amino acids Lys, Arg and Asn show the presence of positively
charged ε-amino group (exposed), positively charged guanidino group
and the amide group that does not carry a formal charge under any
biologically relevant pH, respectively. While in-depth biochemical
analysis of the interaction between amide group of Asn65 and
guanidium group of Arg72 is required to pin point the differences
between K65R and K65N RTs, we speculate that suboptimal interaction
of amidegroupof asparaginewithArg72 leading to improperpositioning
of dNTP for base pairing resulted in a reduced processivity of K65NRT in
comparison to K65R RT.
While K65N mutation has been observed in different HIV-1
subtypes: B, C, CRF01_AE and CRF02_AG; due to the rare occurrence
of K65N in sequences derived from treated subjects, this mutation is
excluded from consideration-criteria for identifying surveillance drug-
resistancemutations (SDRMs) (Shafer et al., 2007; Bennett et al., 2009).
However, understanding of rarely occurring mutations at molecular
level is important as such mutations result in a virus which is highly
crippled for replication. In summary, we have shown here that K65N
viruses are attenuated in comparison to K65R andwild type viruses, and
K65N RT has a decreased processivity in comparison to RT containing
K65R mutation. Furthermore, the deleterious effect on viral replication
by various changes at RT codon 65 could not be compensated by the
addition of L74V on the same viral genome. Our observations suggest
that due to the slower growth kinetics of K65N viruses in comparison to
K65R, the selection of the K65Rmutationmay be favored in clinical use
of antiretroviral drugs compared to K65N. An anti-retroviral therapy
Table 2
Effect of amino acid polymorphism at RT codon 65 on the viral replication in MT-2 cells.
Viruses RT Activity (3H cpm/ml)
Day 7 Day 14
NL4-3 3.3×106 5.0×106
K65R/K65R+L74V 1.5×106/NGa 2.7×106 /1.5×104
K65N/K65 N+L74V 7.0×104/4.5×104 2.0×105/1.2×104
K65A/K65A+L74V 1.7×104/8.3×103 1.4×104/9.4×103
K65E/K65E+L74V 1.4×104/1.5×104 9.8×103/4.5×104
K65Q/K65Q+L74V 1.8×103/2.2×104 1.0×104/1.5×104
K65I/K65Q+L74V 1.3×104/3.1×104 8.0×103/6.0×103
K65T/K65T+L74V 1.6×104/ 4.8×104 8.3×103/8.1×103
RT activity of point mutant/RT activity of double mutant.
a NG, no growth.
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genome may be a useful strategy for the management of HIV disease.
Materials and methods
Chemicals and medium
Radionucleotides, (methyl-3H)dTTP and [α-32P]dTTP were pur-
chased from Perkin Elmer, (Shelton, CT); poly(rC)-poly(dG)12–18 was
purchased from Amersham Pharmacia Biotech, (Piscataway, NJ); and
Polynucleotide poly(rA) and primer oligo(dT)12–18 were purchased
from Boehringer Mannheim (IN). The oligonucleotides used for
mutagenesis were synthesized and high pressure liquid chromatogra-
phy puriﬁed by Diversiﬁed Biopharma Solutions Inc. (Loma Linda, CA).
Complete Dulbecco's Modiﬁed Eagles Medium (DMEM) containing 10%
heat inactivated fetal bovine serum (FBS) and penicillin/streptomycin
was used to grow 293T cells. Complete RPMI medium containing 20%
FBS, 26 IU of IL-2, penicillin/streptomycin and glutamine was used to
culture Peripheral blood mononuclear (PBM) cells. MT-2 cells were
grown in RPMI containing 10% FBS, penicillin/streptomycin and
glutamine.
Cells and virus
PBMcellswere prepared fromBuffy coats received from commercial
vendors (LifeSouth Community Blood Center, Atlanta, GA) using Ficoll
gradients. Primary human embryonic kidney cells 293T, indicator cell
line HeLa-CD4-LTR-β-galactosidase and proviral clone pNL4-3 (Adachi
et al., 1986; Kimpton and Emerman, 1992)were obtained from theAIDS
Research and Reference Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases, National Institute of Health.
Site-speciﬁc mutagenesis and generation of mutant viruses
Various point mutations were created in the background of
proviral clone pNL4-3 by using pALTER−1 mutagenesis system of
Promega (Madison,WI) andmutagenic primers (Table 1) according toTable 3
Drug susceptibility of recombinant viruses containing K65R and K65N mutation.
Viruses Fold change in EC50
Drug concentrations (μM)
Tenofovir (TFV) Didanosine (ddI)
WT (pNL4-3) 0.03±0.01 0.08±0.02
K65R 0.18±0.05 (6.0)a 0.42±0.03 (5.2)a
K65N 0.16±0.02 (5.3)a 0.48±0.05 (6.0)a
The values shown were obtained from three independent ACTG/DoD drug
susceptibility assays.
a The values in the bracket show -fold changes with respect to WT viruses.manufacturer's guidelines and our previously described protocols
(Sharma and Crumpacker, 1999; Sharma et al., 2009). Mutants K65R
and K65R+L74V that have been previously analyzed for replication
capacity and in vitro RT processivity were used as controls (Sharma
et al., 2004b; Sharma et al., 2009). Viruses were produced using
SuperFectR reagent (Quiagen, Valencia, CA) and manufacturer's
guidelines. Cells (293T) were split into 60×10 mm dishes
24 h–48 h prior to transfection. To generate virus the complex
containing 10 μg of DNA in 150 μl of serum-free medium and 30 μl of
SuperFect reagent was incubated at room temperature for 10 min.
One ml of complete DMEM was added drop by drop onto 293 cells
that were washed once with phosphate buffer saline (PBS). Cells were
incubated at 37 °C in the presence of 5% CO2 for 3 h. The remaining
medium-complex was removed and the cells were washed with 4 ml
of PBS. Four milliliters of complete DMEMwas added and dishes were
incubated for 72 h–96 h. Culture supernatants were collected and
centrifuged for 5 min at 833g (g=1.2) to pellet any debris. Culture
supernatants were ﬁltered (0.22 μm) and saved in aliquots of 0.5 ml
and 1 ml at −80 °C. Viral RNA was isolated by QiAamp® viral RNA
mini kit (Qiagen Sciences, Valencia, CA). RT PCR was performed using
Superscript™ III one-step RT PCR system (Invitrogen, Carlsbad, CA).
All the stock viruses were conﬁrmed for desired mutations by
sequencing viral RNA using primer 74F, 5′-GTAGGACCTACACCT
GTCAAC-3′ (Nurpeisov et al., 2003).
Quantiﬁcation of virus
BothHIV-1 antigen p24 concentrations aswell as RT activity for each
stock virus were determined as described previously (Sharma and
Crumpacker 1997; Sharma et al., 2004). Brieﬂy, antigen p24 determi-
nationwasdone according to themanufacturer's protocol usingAntigen
p24CA ELISA kit (NCI, Frederick,MD). To determineRT activity, oneml of
each virus was centrifuged for 2 h at 15,000 rpm in a refrigerated
centrifuge [Heraeus Instruments Corp., Model, Biofuge 15R; Rotor,
3743]. Pelleted virionswere lysed with 50–100 μl of virus solubilization
buffer (0.5% Triton X-100, 50 mM Tris, pH 7.8, 800 mM NaCl, 0.5 mM
PMSF, 20%Glycerol), 10 μl of samples in triplicateweremixedwith75 μl
of RT assay buffer (60 mM Tris, pH 7.8, 12 mM MgCl2, 6 mM
Dithiothreitol, 7 μg dATP) in the presence of 450 ng of poly (rA)-Oligo
(dT) and 5 μCi of methyl-3H TTP and reactions were incubated at 37 °C
for 2 h. Entire reactionmixturewas overlaid onDE81ﬁlter (Whattman).
Filters were washed 3 times with 2X SSC buffer, 2 times with absolute
alcohol, air dried and the radioactivity was measured in scintillation
ﬂuid.
Determination of viral titer
Viruses produced in 293T cells were quantiﬁed in HeLa-CD4-LTR-β-
galactosidase cell lines as described elsewhere (Kimpton and Emerman,
1992). Brieﬂy, 20–30% conﬂuent cells in 12-well plate were infected
with stock viruses containing 1, 10 and 100 ng antigen p24 in the
presence of 20 μg of DEAE-dextran (Pharmacia) perml. The plateswere
rocked intermittently every 30 min until 120 min and then 1 ml of
DMEM with 10% calf serum was added to each well. After 48 h, the
medium was removed and the cells were ﬁxed at room temperature
with 2 ml of phosphate-buffered saline (PBS) containing 1% formalde-
hyde and 0.2% glutaraldehyde for 5 min. The cells were washed four
times with PBS and incubated for 50 min at 37 °C in 500 μl of a solution
of 4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 2 mM
MgCl2, and 0.4 mg of X-Gal per ml. The reaction was stopped by
decanting the staining solution and washing the cells thrice with PBS.
Blue cells were counted at 100× magniﬁcation of a light microscope.
Infectiousunitswere calculatedby counting thenumber of blue colonies
in each dilution and the amount of HIV-1 p24 capsid antigen by ELISA.
The amount of virus (antigen p24) required to infect 1 cell was
40 H. Chunduri et al. / Virology 414 (2011) 34–41considered equivalent to 1 infectious unit (IU) or multiplicity of
infection (MOI) 1.
Replication kinetics assays
Healthy donor's PBMcellswere infected at variousMOIs (0.001, 0.01
and 1.0) based upon the IU (infection units). Replication kinetics assays
were performed by infecting 10×106 PHA-stimulated PBM cells with
equivalent amount of viruses. Culture supernatants were collected
every other day until day 14 to determine RT activity and genomic RNA
sequence. In a parallel experiment 3.0×106 MT-2 cells (0.5×106/ml)
were infected with 0.001 IU of various viruses and replication kinetics
were measured by monitoring HIV-1 antigen p24 and RT activity until
day 14. The relative RC values were calculated during multiple
replication cycles. Themedianvalues ofHIV antigenp24were calculated
for WT (100%) in three independent assays. RCs for K65R and K65N
were calculated by dividing median antigen p24 values of mutant
viruses by the median values obtained for WT virus for a speciﬁc time
point.
Drug susceptibility assays
In order to compare the impact of various mutations on the
susceptibility to tenofovir (TFV) and ddI, we performed PBM cell-
basedACTG/DoDdrugsusceptibility assaysdescribed elsewhere (Japour
et al., 1993). Three independent assayswere performed and EC50 values
were calculated using GraphPad Prism 5 software analysis.
In vitro RT processivity assay
Since various viral (nucleocapsid proteins, integrase) and host
factors (p53 and cellular topoisomerase) have been shown to interact
with HIV-1 RT (Takahashi et al., 1995; Li et al., 1996; Druillennec et al.,
1999; Negroni and Buc, 1999; Bakhanashvili, 2001; Hehl et al., 2004;
Anthony and Destefano, 2007; Wilkinson et al., 2009), we compared
virion-associatedRTs ofmutant andwild type viruses in all of our assays.
RT processivity assays were performed as described elsewhere (Boyer
and Hughes, 1995; Back et al., 1996; Sharma et al., 2009). Brieﬂy, stock
viruses supernatants containing3000 ngequivalent of antigenp24were
centrifuged at 16,000 rpm for 2 h at 4 °C. RT was dislodged from the
pelleted virions by the treatment of 50 μl of 0.5% NP40. The RT activity
was determined using homopolymer template/primer [poly rA-oligo d
(T)] andα-32P dTTP according to published protocols (Back et al., 1996;
Sharmaet al., 2009). Different amounts (2 μl and 4 μl) of RT lysateswere
incubated with 2 μg/ml of poly (rA) and 0.32 μg/ml of oligonucleotide
(dT) in thepresenceof anassaymixture containing60 mMTris (pH7.8),
75 mM KCl, 5 mM MgCl2, 0.1% NP40, 1 mM EDTA, and 4 mM DTT at
37 °C for 30 min in the absence of radiolabeleddTTP. After the formation
of template–primer–enzyme complex, cDNA synthesis was initiated by
the addition of 50 μCi of [α-32P] dTTP/ml and 50-fold excess of trap [poly
(rC)-oligo (dG)]. The reactions were terminated after 180 min by
placing the tubes in ice slurry and addition of the equal volume of
buffered phenol. cDNA products were extracted once with phenol:
chloroform (25:24) followed by one extraction with buffer-saturated
chloroform. The puriﬁed products were run on 6% polyacrylamide
sequencing gel electrophoresis at 30W for 2 h. The wet gels were
exposed to autoradiography for 30 min to 2 h. To determine relative
density of bands in the gel, we scanned group of bands using Bio Image
Intelligent QuantiﬁerR software (Bio Image Systems, Inc, Jackson, MI).
Statistical analysis
To compare the replication capacity (RC) of mutant viruses in
relation to wild type virus, RC values for 3 independent replication
assays were calculate for mutant viruses. A paired analysis with student
t-test was performed and p=b0.5 were considered as signiﬁcantdifference. Statistical analysis was conducted to determine the
differences in processivity between WT and mutant viruses or among
mutant viruses K65R and K65N during a single processivity cycle. This
analysis was designed to test the hypothesis that for wild type and
mutant RTs, cDNA density decreases at the same rate as DNA band
number increases. Three to ﬁve independent processivity assays were
performed for each RT and statistical values that includemean, median,
standard deviation and maximum and minimum were obtained. A
paired analysis with t-test was performed to compare the density of
cDNA products generated by various RTs and p=b0.05 was considered
signiﬁcant difference (Sharma and Crumpacker, 1999).Acknowledgments
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